Industry News
Biotechnology Industry News
In an Oct. 9 discussion about…
In an Oct. 9 discussion about innovation, resilience and the road ahead, panelists explored how federal uncertainty has affected the biotech sector, while also highlighting potential silver linings in the current environment.
The stars have aligned for Bristol…
The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a
Shuttle Pharmaceuticals has…
Shuttle Pharmaceuticals has rocketed into the AI-driven drug discovery space via the planned $10 million acquisition of Molecule.ai.
It’s still early in the season,…
It’s still early in the season, but Evommune has become the latest indicator that drug developers are once again tempted by the public markets.
Regeneron has posted updated…
Regeneron has posted updated clinical data on DB-OTO, providing more evidence of the gene therapy’s potential to treat a rare genetic form of deafness.
Transparency is often a word…
Transparency is often a word pharma companies like to use, but in practice, they rarely live up to the ideal. AstraZeneca is trying to be truly transparent with its new Discovery Centre.
Patient-centric strategies and…
Patient-centric strategies and global partnerships drive progress in eye disease research
Two ex-Moderna leaders have hit a…
Two ex-Moderna leaders have hit a milestone in their new endeavor, closing a $325 million inaugural fund for their biotech venture capital firm called Ascenta.
Peter Marks, M.D., Ph.D., the…
Peter Marks, M.D., Ph.D., the former head of the FDA’s Center for Biologics Evaluation and Research (CBER), has joined Eli Lilly as senior vice president of molecule discovery and head of infectious disease. Marks served
In the world of clinical trials,…
In the world of clinical trials, patient recruitment is an ongoing challenge.
Discover how artificial…
Discover how artificial intelligence and real-world data are reshaping biotech, driving smarter trials and patient-centered breakthroughs.
Expedition Therapeutics is gearing…
Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures
Ono Pharmaceutical’s EP4…
Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer.
England’s AviadoBio is looking to…
England's AviadoBio is looking to China as a potential source of additional gene therapies, securing an option to a $413 million biobucks deal that could deliver a rare eye disease candidate.
Novo Nordisk has struck a deal to…
Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market.
Catalent has continued its foray…
Catalent has continued its foray into the antibody-drug conjugate space, this time penning a $10 million biobucks pact to evaluate Lisata’s tumor drug.
After axing a vast array of…
After axing a vast array of federal research projects and grants, a recent slew of awards paints a picture of the types of science that the second Trump administration will back: in vivo cell therapies.
AAIC 2025 spotlights inflammation…
AAIC 2025 spotlights inflammation in Alzheimer’s; InMed’s INM-901 reduces key biomarkers linked to disease progression
Arthrosi Therapeutics has raised…
Arthrosi Therapeutics has raised $153 million to bankroll its bid to clout gout. The series E financing gives the biotech the financial firepower to deliver data from two phase 3 trials next year.
In a pair of deals, TransCode has…
In a pair of deals, TransCode has bagged a phase 3 cancer vaccine and a $25 million injection into its cash-strapped coffers.